ISCF Grand Challenge: Ageing Society (4 results found)
ISCF Grand Challenge: Ageing Society
The UK population is ageing, as it is across the industrialised world. The prospect of longer lives will require people to plan their careers and retirement differently. Ageing populations will create new demands for technologies, products and services, including new care technologies, new housing models and innovative savings products for retirement. We have an obligation to help our older citizens lead independent, fulfilled lives, continuing to contribute to society.
If we succeed, we will create an economy which works for everyone, regardless of age.
Ensure that people can enjoy at least 5 extra healthy, independent years of life by 2035, while narrowing the gap between the experience of the richest and poorest.
We are living longer lives because of medical advances, better drugs, healthier lifestyles, and safer workplaces. A girl born in the UK today has a 1 in 3 chance of living to 100, and the chance of living to 100 will double in the next 50 years. Given this trend, it’s time to radically rethink how we respond, at each stage in life, to the way that we we support our families and communities, as well as the way that we approach work, finances, health and care, and housing.
This mission aims to ensure that people can enjoy at least 5 extra healthy, independent years of life by 2030, while narrowing the gap between the experience of the richest and poorest. Success in this mission will help people remain independent for longer, continue to participate through work and within their communities, and stay connected to others to counter the epidemic of loneliness.
The mission will help:
- support people to remain at work for longer
- build markets for consumer products and services that better met the needs of older people
- drive improvements in public health and innovate across the social care sector.
Through the Industrial Strategy Fund, we have already invested £98 million for innovation in Healthy Ageing. This mission will also be supported by the £210 million investment in Data to Early Diagnostics and Precision Medicine.